Trending Topic

14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Isabella Henderson, Nisali A Gunawardane, Ruben I Kuzniecky

Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1 Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and sudden unexpected death in epilepsy (SUDEP).2 Early identification of DRE is critical to enable timely exploration […]

Tim Bartels: Highlights at AD/PD 2022

3
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 28th 2022

Dr Tim Bartels (UK Dementia Research Institute, University College London, London, UK) joins touchNEUROLOGY to discuss the highlights from this year’s AD/PD 2022 conference. He discusses some of his personal highlights in the field of new therapeutics for neurodegeneration, and also the presentation of functioning MRI agents for α-Synuclein.

Question:

  1. What are some of the highlights from this year’s AD/PD 2022 Meeting?

Disclosures: Tim Bartels has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Filmed as a highlight of AD/PD 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup